Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Centessa Pharmaceuticals Plc ADR (NQ: CNTA ) 16.26 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Centessa Pharmaceuticals Plc ADR < Previous 1 2 3 4 5 Next > Wake Up to This Biotech Stock That Still Has Big Potential Upside September 28, 2024 Centessa Pharmaceuticals released strong results in Phase 1 trials and now Wall Street analysts are buzzing over the stock. Via MarketBeat Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) September 26, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares September 12, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares September 11, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers September 10, 2024 Centessa Pharmaceuticals revealed promising interim Phase 1 trial results for ORX750, demonstrating significant improvements in sleep latency for acutely sleep-deprived healthy volunteers. The company... Via Benzinga Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday September 10, 2024 Via Benzinga Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity September 10, 2024 The company tested a potential narcolepsy treatment in healthy, but sleep-deprived, volunteers. Via Investor's Business Daily Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers September 10, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) August 27, 2024 ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS) From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference August 21, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire CNTA Stock Earnings: Centessa Pharmaceuticals Misses EPS for Q2 2024 August 13, 2024 CNTA stock results show that Centessa Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 August 13, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer June 10, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences May 21, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024 May 13, 2024 CNTA stock results show that Centessa Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 May 13, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares April 23, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares April 23, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 April 22, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023 March 28, 2024 CNTA stock results show that Centessa Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 March 28, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire 7 Biotech Stocks Ready to Ride the Sector’s Resurgence March 18, 2024 With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. Via InvestorPlace Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference February 22, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday February 09, 2024 U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday. Shares of SPS Commerce, Inc. (NASDAQ: SPSC) rose sharply during Friday’s session following upbeat results. Via Benzinga Topics Stocks Exposures US Equities Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session February 09, 2024 Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results. Via Benzinga Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and February 09, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences January 22, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference December 13, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia December 10, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session November 27, 2023 Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.